NYXOAH SA (NYXH) Fundamental Analysis & Valuation

NASDAQ:NYXH • BE0974358906

Current stock price

3.09 USD
+0.03 (+0.98%)
At close:
3.1186 USD
+0.03 (+0.93%)
After Hours:

This NYXH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NYXH Profitability Analysis

1.1 Basic Checks

  • In the past year NYXH has reported negative net income.
  • In the past year NYXH has reported a negative cash flow from operations.
  • In the past 5 years NYXH always reported negative net income.
  • In the past 5 years NYXH always reported negative operating cash flow.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a Return On Assets value of -89.29%, NYXH is not doing good in the industry: 78.80% of the companies in the same industry are doing better.
  • NYXH has a Return On Equity of -164.01%. This is in the lower half of the industry: NYXH underperforms 71.20% of its industry peers.
Industry RankSector Rank
ROA -89.29%
ROE -164.01%
ROIC N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • NYXH's Gross Margin of 64.36% is fine compared to the rest of the industry. NYXH outperforms 68.48% of its industry peers.
  • NYXH's Gross Margin has been stable in the last couple of years.
  • NYXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. NYXH Health Analysis

2.1 Basic Checks

  • NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NYXH has been increased compared to 1 year ago.
  • Compared to 5 years ago, NYXH has more shares outstanding
  • The debt/assets ratio for NYXH is higher compared to a year ago.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • NYXH has an Altman-Z score of -5.06. This is a bad value and indicates that NYXH is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.06, NYXH is doing worse than 71.74% of the companies in the same industry.
  • A Debt/Equity ratio of 0.40 indicates that NYXH is not too dependend on debt financing.
  • NYXH has a Debt to Equity ratio (0.40) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -5.06
ROIC/WACCN/A
WACC7.33%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.70 indicates that NYXH should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.70, NYXH is not doing good in the industry: 69.57% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.41 indicates that NYXH should not have too much problems paying its short term obligations.
  • NYXH has a worse Quick ratio (1.41) than 61.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.41
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NYXH Growth Analysis

3.1 Past

  • NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
  • NYXH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.96%.
  • The Revenue has been growing by 74.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.37% on average over the next years.
  • NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 117.81% yearly.
EPS Next Y-22.05%
EPS Next 2Y-9.49%
EPS Next 3Y3.37%
EPS Next 5YN/A
Revenue Next Year66.9%
Revenue Next 2Y138.83%
Revenue Next 3Y137.9%
Revenue Next 5Y117.81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. NYXH Valuation Analysis

4.1 Price/Earnings Ratio

  • NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.49%
EPS Next 3Y3.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NYXH Dividend Analysis

5.1 Amount

  • No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NYXH Fundamentals: All Metrics, Ratios and Statistics

NYXOAH SA

NASDAQ:NYXH (3/19/2026, 8:20:08 PM)

After market: 3.1186 +0.03 (+0.93%)

3.09

+0.03 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners21.79%
Inst Owner Change34.94%
Ins Owners19.69%
Ins Owner ChangeN/A
Market Cap134.91M
Revenue(TTM)5.64M
Net Income(TTM)-83.57M
Analysts81.43
Price Target11.28 (265.05%)
Short Float %0.98%
Short Ratio5.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.07%
Min EPS beat(2)-5.02%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.98%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)5
Avg EPS beat(8)-2.41%
EPS beat(12)6
Avg EPS beat(12)-9.44%
EPS beat(16)9
Avg EPS beat(16)-3.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-1.4%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-19.45%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.3%
Revenue beat(8)1
Avg Revenue beat(8)-18.47%
Revenue beat(12)1
Avg Revenue beat(12)-25.3%
Revenue beat(16)1
Avg Revenue beat(16)-32.33%
PT rev (1m)-0.22%
PT rev (3m)-3.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.87%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)32.3%
Revenue NY rev (1m)12.58%
Revenue NY rev (3m)10.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.8
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 138.67
EV/EBITDA N/A
EPS(TTM)-2.58
EYN/A
EPS(NY)-2.48
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.15
BVpS1.34
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.29%
ROE -164.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.36%
FCFM N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.99%
Cap/Sales 21.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.41
Altman-Z -5.06
F-Score3
WACC7.33%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.02%
EPS Next Y-22.05%
EPS Next 2Y-9.49%
EPS Next 3Y3.37%
EPS Next 5YN/A
Revenue 1Y (TTM)10.96%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%55.77%
Revenue Next Year66.9%
Revenue Next 2Y138.83%
Revenue Next 3Y137.9%
Revenue Next 5Y117.81%
EBIT growth 1Y-59.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.75%
EBIT Next 3Y-14.54%
EBIT Next 5Y11.04%
FCF growth 1Y-49.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.83%
OCF growth 3YN/A
OCF growth 5YN/A

NYXOAH SA / NYXH Fundamental Analysis FAQ

What is the fundamental rating for NYXH stock?

ChartMill assigns a fundamental rating of 2 / 10 to NYXH.


Can you provide the valuation status for NYXOAH SA?

ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH). This can be considered as Overvalued.


Can you provide the profitability details for NYXOAH SA?

NYXOAH SA (NYXH) has a profitability rating of 1 / 10.


What is the financial health of NYXOAH SA (NYXH) stock?

The financial health rating of NYXOAH SA (NYXH) is 2 / 10.


Can you provide the expected EPS growth for NYXH stock?

The Earnings per Share (EPS) of NYXOAH SA (NYXH) is expected to decline by -22.05% in the next year.